Clinical Trials
9 trialsNCT03910660 2026-05-15
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
BioXcel Therapeutics Inc
Phase 1/2 Completed
NCT05703542 2025-07-18
BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT04171219 2025-05-16
Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00489710 2023-08-22
Talabostat in Treating Patients With Metastatic Kidney Cancer
University of Nebraska
Phase 2 Withdrawn
NCT04123574 2022-02-24
A Pilot Study of BXCL701 in Patients With Pancreatic Cancer
BioXcel Therapeutics Inc
Phase EARLY_PHASE1 Withdrawn
NCT00086203 2015-03-25
Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)
FDA Office of Orphan Products Development
Phase 2 Completed
NCT00303940 2012-03-15
Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00116389 2007-06-08
Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas
Point Therapeutics
Phase 2 Terminated
NCT00243204 2007-06-08
Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy
Point Therapeutics
Phase 3 Terminated